HC Wainwright & Co. reiterates Buy rating on Connect Biopharma Hldgs, $7 price target

HC Wainwright & Co. maintained a Buy rating on Connect Biopharma Hldgs with a $7 price target, implying a 614.5% upside from the last close. The firm cited strong clinical data and upcoming regulatory milestones as key catalysts. Recent analyst price targets range from $5 to $7.

Original reporting
Published Oct 2, 2026, 10:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 10:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. reiterates Buy rating on Connect Biopharma Hldgs, $7 price target — source image
Decision brief

The 30-second read

$CNTBBullishMed
01

Why it matters

The new efficacy data and higher target are likely to attract buying interest, especially in a thinly traded microcap.

02

Market read

Provides fresh clinical data and analyst upgrade for CNTB, creating a short-term trading catalyst.

03

What to watch

Potential delays in FDA discussions and competition from other COPD therapies could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Analyst note from HC Wainwright reiterates a Buy rating and raises price target to $7 based on new COPD trial data.

Company-level read

Ticker impact

$CNTBBullishHigh confidence
Context

HC Wainwright reiterated a Buy rating on Connect Biopharma Hldgs (CNTB) and highlighted new Phase 2 data showing 81% reduction in COPD treatment failure.

Expected impact

likely upward pressure as investors price in the efficacy data and higher target.

Evidence & confidence

Trial results are material for a biotech and the analyst upgrade adds credibility, driving demand.

Market effects

Boosts sentiment for respiratory biotech sector and may lift peers with similar pipelines.

Limited to US biotech investors; no broader regional effect.

Modest, primarily affecting niche biotech investors.

Counterpoint

Skeptics may question the durability of the data and regulatory timeline, suggesting caution.

Key entities

  • Connect Biopharma Holdings

    Biotech developing respiratory therapies, ticker CNTB.

  • HC Wainwright & Co.

    Equity research firm issuing the rating and target.

Related articles

$CNTBMed

Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma Holdings Ltd (CNTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update – Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and c

$CNTBHighAI 9/10

Why is Connect Biopharma stock surging today?

Connect Biopharma (CNTB) stock rose 17.4% to $1.165 after positive Phase 2 trial results for its COPD treatment, rademikibart. The drug showed significant efficacy, reducing treatment failure rates and exacerbations. BTIG lowered its price target to $5.00 but maintained a Buy rating. Analysts generally remain positive, with a consensus price target of $6.14. The company plans to discuss Phase 3 development with the FDA. The broader market also gained due to softer inflation data.

$CNTBHighAI 8/10

BTIG cuts Connect Biopharma stock price target on trial timeline

BTIG reduced its price target for Connect Biopharma (CNTB) to $5.00 from $10.00, maintaining a Buy rating. The stock is down 65% YTD. The company's Seabreeze STAT COPD trial met its primary endpoint, showing an 81% reduction in treatment failure rate. BTIG lowered success probabilities and pushed launch timelines to 2030. Other analysts have mixed reactions, with some reiterating Buy ratings and others adjusting targets.